Evidence map›Paper›PMID 38778399›Full record

ArticleMalaria journal2024

Can neonicotinoid and pyrrole insecticides manage malaria vector resistance in high pyrethroid resistance areas in Côte d'Ivoire?

Armand K Ekra, Constant A V Edi, Guy Constant N Gbalegba, Julien Z B Zahouli, Mathias Danho, Benjamin G Koudou

Abstract read
In one paragraph

Article in Malaria journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Armand K EkraUMRI 28, Sciences Agronomiques et Procédés de Transformation, Laboratoire de Zoologie Agricole et Entomologie, Institut National Polytechnique Félix Houphouët-Boigny (INP-HB), Yamoussoukro, République de Côte d'Ivoire. armand.ekra@csrs.ci.
Constant A V EdiCentre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, République de Côte d'Ivoire.
Guy Constant N GbalegbaProgramme National de Lutte Contre le Paludisme, Abidjan, République de Côte d'Ivoire.
Julien Z B ZahouliCentre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, République de Côte d'Ivoire.
Mathias DanhoUMRI 28, Sciences Agronomiques et Procédés de Transformation, Laboratoire de Zoologie Agricole et Entomologie, Institut National Polytechnique Félix Houphouët-Boigny (INP-HB), Yamoussoukro, République de Côte d'Ivoire.
Benjamin G KoudouCentre Suisse de Recherches Scientifiques en Côte d'Ivoire, Abidjan, République de Côte d'Ivoire.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnopheles mosquito resistance to insecticide remains a serious threat to malaria vector control affecting several sub-Sahara African countries, including Côte d'Ivoire, where high pyrethroid, carbamate and organophosphate resistance have been reported. Since 2017, new insecticides, namely neonicotinoids (e.g.; clothianidin) and pyrroles (e.g.; chlorfenapyr) have been pre-qualified by the World Health Organization (WHO) for use in public health to manage insecticide resistance for disease vector control.

methodsClothianidin and chlorfenapyr were tested against the field-collected Anopheles gambiae populations from Gagnoa, Daloa and Abengourou using the WHO standard insecticide susceptibility biossays. Anopheles gambiae larvae were collected from several larval habitats, pooled and reared to adulthood in each site in July 2020. Non-blood-fed adult female mosquitoes aged 2 to 5 days were exposed to diagnostic concentration deltamethrin, permethrin, alpha-cypermethrin, bendiocarb, and pirimiphos-methyl. Clothianidin 2% treated papers were locally made and tested using WHO tube bioassay while chlorfenapyr (100 µg/bottle) was evaluated using WHO bottle assays. Furthermore, subsamples of exposed mosquitoes were identified to species and genotyped for insecticide resistance markers including the knock-down resistance (kdr) west and east, and acetylcholinesterase (Ace-1) using molecular techniques.

resultsHigh pyrethroid resistance was recorded with diagnostic dose in Abengourou (1.1 to 3.4% mortality), in Daloa (15.5 to 33.8%) and in Gagnoa (10.3 to 41.6%). With bendiocarb, mortality rates ranged from 49.5 to 62.3%. Complete mortality (100% mortality) was recorded with clothianidin in Gagnoa, 94.9% in Daloa and 96.6% in Abengourou, while susceptibility (mortality > 98%) to chlorfenapyr 100 µg/bottle was recorded at all sites and to pirimiphos-methyl in Gagnoa and Abengourou. Kdr-west mutation was present at high frequency (0.58 to 0.73) in the three sites and Kdr-east mutation frequency was recorded at a very low frequency of 0.02 in both Abengourou and Daloa samples and absent in Gagnoa. The Ace-1 mutation was present at frequencies between 0.19 and 0.29 in these areas. Anopheles coluzzii represented 100% of mosquitoes collected in Daloa and Gagnoa, and 72% in Abengourou.

conclusionsThis study showed that clothianidin and chlorfenapyr insecticides induce high mortality in the natural and pyrethroid-resistant An. gambiae populations in Côte d'Ivoire. These results could support a resistance management plan by proposing an insecticide rotation strategy for vector control interventions.

Indexed as

AnophelesInsecticide ResistanceInsecticidesMosquito VectorsPyrethrinsAnimalsCote d'IvoireFemaleGuanidinesLarvaMalariaMosquito ControlNeonicotinoidsPyrrolesThiazoleschlorfenapyrclothianidinGuanidinesInsecticidesNeonicotinoidsPyrethrinsPyrrolesThiazolesAnopheles gambiaeChlorfenapyrClothianidinCôte d’IvoireInsecticide resistanceMalaria

Identifiers

PMID38778399
PMCPMC11112771

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.